Bristol Myers Squibb RXFP1 compound 39

Bristol Myers Squibb RXFP1 compound 39: sourced facts only. name: "Exploration of chemical space around previously reported anthranilamide 2 led to the discovery of lead compound 39 with significantly improved agonist activities toward human and rodent RXFP1." [PMID:40434342]; target: "Exploration of chemical space around previously reported anthranilamide 2 led to the discovery of lead compound 39 with significantly improved agonist activities toward human and rodent RXFP1." [PMID:40434342]; developer: "Research and Development, Bristol Myers Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States." [PMID:40434342]; stage: "Compound 39 also elicited significant interpubic ligament (IPL) expansion in C57BL/6 mouse, measured with microCT imaging, which recapitulated the effect of relaxin." [PMID:40434342]